ZA201406323B - Triazolo[4,5-d]pyrimidine derivatives - Google Patents
Triazolo[4,5-d]pyrimidine derivativesInfo
- Publication number
- ZA201406323B ZA201406323B ZA2014/06323A ZA201406323A ZA201406323B ZA 201406323 B ZA201406323 B ZA 201406323B ZA 2014/06323 A ZA2014/06323 A ZA 2014/06323A ZA 201406323 A ZA201406323 A ZA 201406323A ZA 201406323 B ZA201406323 B ZA 201406323B
- Authority
- ZA
- South Africa
- Prior art keywords
- triazolo
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000558 | 2012-01-28 | ||
| PCT/EP2012/005358 WO2013110309A1 (en) | 2012-01-28 | 2012-12-21 | Triazolo[4,5-d]pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201406323B true ZA201406323B (en) | 2016-08-31 |
Family
ID=47561514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/06323A ZA201406323B (en) | 2012-01-28 | 2014-08-27 | Triazolo[4,5-d]pyrimidine derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9409914B2 (enExample) |
| EP (1) | EP2807161B1 (enExample) |
| JP (1) | JP6063482B2 (enExample) |
| KR (1) | KR20140117636A (enExample) |
| CN (1) | CN104066734B (enExample) |
| AR (1) | AR089810A1 (enExample) |
| AU (1) | AU2012367141B2 (enExample) |
| BR (1) | BR112014016884A2 (enExample) |
| CA (1) | CA2862694C (enExample) |
| ES (1) | ES2655264T3 (enExample) |
| IL (1) | IL233808B (enExample) |
| MX (1) | MX2014008864A (enExample) |
| SG (1) | SG11201404234YA (enExample) |
| WO (1) | WO2013110309A1 (enExample) |
| ZA (1) | ZA201406323B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014264973B2 (en) * | 2013-05-06 | 2018-01-18 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| WO2016169504A1 (zh) * | 2015-04-24 | 2016-10-27 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| SI3498693T1 (sl) | 2016-08-10 | 2025-02-28 | Takeda Pharmaceutical Company Limited | Heterociklična spojina |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| KR102328423B1 (ko) * | 2018-09-11 | 2021-11-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 트리아졸로-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20220040183A1 (en) * | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
| WO2021222147A1 (en) * | 2020-04-27 | 2021-11-04 | Hibercell, Inc. | Heterocyclic gcn2 modulators |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| KR20250122240A (ko) | 2024-02-06 | 2025-08-13 | 한미약품 주식회사 | 신규한 함질소 헤테로고리 유도체 및 이의 용도 |
| WO2025179188A1 (en) * | 2024-02-22 | 2025-08-28 | Juno Therapeutics, Inc. | Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing |
| CN120504636B (zh) * | 2025-07-22 | 2025-10-31 | 江西中医药大学 | 一种磺胺噻唑-甲氧苄啶药物晶盐及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| AU2001266233B2 (en) | 2000-07-07 | 2006-06-29 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| JP2009514782A (ja) | 2003-07-16 | 2009-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ３阻害剤としてのトリアゾロピリミジン誘導体 |
| ES2464281T3 (es) | 2004-07-19 | 2014-06-02 | The Johns-Hopkins University | Inhibidores de FLT3 para la inmunosupresión |
| DE102004051827A1 (de) | 2004-10-25 | 2006-05-04 | Hörmann KG Antriebstechnik | Armbandsender |
| ES2508766T3 (es) | 2004-10-29 | 2014-10-16 | Janssen R&D Ireland | Derivados de pirimidina bicíclicos que inhiben el VIH |
| AU2006205808A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| KR20120102601A (ko) | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
-
2012
- 2012-12-21 AU AU2012367141A patent/AU2012367141B2/en not_active Ceased
- 2012-12-21 KR KR1020147023872A patent/KR20140117636A/ko not_active Withdrawn
- 2012-12-21 CN CN201280068233.4A patent/CN104066734B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/EP2012/005358 patent/WO2013110309A1/en not_active Ceased
- 2012-12-21 MX MX2014008864A patent/MX2014008864A/es unknown
- 2012-12-21 JP JP2014553622A patent/JP6063482B2/ja not_active Expired - Fee Related
- 2012-12-21 US US14/375,067 patent/US9409914B2/en not_active Expired - Fee Related
- 2012-12-21 ES ES12816002.5T patent/ES2655264T3/es active Active
- 2012-12-21 SG SG11201404234YA patent/SG11201404234YA/en unknown
- 2012-12-21 BR BR112014016884A patent/BR112014016884A2/pt not_active IP Right Cessation
- 2012-12-21 CA CA2862694A patent/CA2862694C/en active Active
- 2012-12-21 EP EP12816002.5A patent/EP2807161B1/en active Active
-
2013
- 2013-01-25 AR ARP130100230A patent/AR089810A1/es unknown
-
2014
- 2014-07-24 IL IL233808A patent/IL233808B/en active IP Right Grant
- 2014-08-27 ZA ZA2014/06323A patent/ZA201406323B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2862694C (en) | 2020-07-28 |
| EP2807161A1 (en) | 2014-12-03 |
| MX2014008864A (es) | 2014-12-15 |
| EP2807161B1 (en) | 2017-10-04 |
| AU2012367141A1 (en) | 2014-09-11 |
| CA2862694A1 (en) | 2013-08-01 |
| CN104066734B (zh) | 2017-03-29 |
| JP2015505541A (ja) | 2015-02-23 |
| ES2655264T3 (es) | 2018-02-19 |
| BR112014016884A2 (pt) | 2017-06-27 |
| AR089810A1 (es) | 2014-09-17 |
| US20140378431A1 (en) | 2014-12-25 |
| US9409914B2 (en) | 2016-08-09 |
| WO2013110309A1 (en) | 2013-08-01 |
| IL233808B (en) | 2018-03-29 |
| JP6063482B2 (ja) | 2017-01-18 |
| CN104066734A (zh) | 2014-09-24 |
| SG11201404234YA (en) | 2014-08-28 |
| AU2012367141B2 (en) | 2016-12-22 |
| KR20140117636A (ko) | 2014-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243092A0 (en) | New triazolo[d–4,5]pyrimidine histories | |
| IL257410A (en) | Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| PT2794611T (pt) | Pirazolo[1,5-a]pirimidinas como agentes antivirais | |
| LT2857404T (lt) | Imidazo[1,2-b]piridazino dariniai, kaip kinazės inhibitoriai | |
| ZA201506570B (en) | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | |
| ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
| SG11201402197UA (en) | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| SG11201401342VA (en) | 5,7-substituted-imidazo[1,2-c]pyrimidines | |
| EP3067356A4 (en) | Pyrrolo pyrimidine derivative | |
| LT2935274T (lt) | 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidino dariniai, skirti kvėpavimo organų ligų gydymui | |
| ZA201403441B (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid | |
| PL2694513T3 (pl) | Pochodne pirazolopirymidynowe | |
| PT2729475E (pt) | Derivados do ácido carboxílico com um anel de oxazolo[4,5-d pirimidina | |
| GB201219129D0 (en) | Triazolo(4,5-d)pyrmindine compounds | |
| AU2011355362B2 (en) | 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives |